Adlai Nortye Ltd. America... (ANL)

Adlai Nortye Ltd. Sponsored ADR (ANL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Elevance Health (ELV) have performed compared to their sector so far this year.

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.

Newly listed Adlai Nortye has yet to bring any products to market and has lost more than $130 million in just over two years. ANL's key drug candidate is a PI3K inhibitor now in global trials, even as...

The third quarter wrapped up with four IPOs and eight pipeline additions. Eight issuers submitted initial filings this past week. The October IPO market looks like it will be off to a quiet start, wit...

There was just one pricing this past week, which was excluded from our IPO stats, while holdover biotech Adlai Nortye did not get done. Filing activity reached a six-month high in August, and six issu...

Three small issuers began trading this past week, two of which were eligible for inclusion in our IPO stats. While most IPOs are biding their time through the August break, the SPAC market is churning...

Adlai Nortye Ltd. has filed for a $72 million IPO for its cancer drug development. The firm's lead candidate, AN2025, is in Phase 2 and Phase 3 trials for solid tumors and head and neck squamous cell ...

Adlai Nortye Ltd. said late Thursday it plans to offer three million American depositary shares at an estimated price of $22 to $26 a share in its initial public offering on the Nasdaq under the symbo...